Jun 12 |
Presenting on the Emerging Growth Conference 72 Day 2 on June 13 Register Now
|
Jun 11 |
Cadrenal Therapeutics to Present at the Emerging Growth Conference on June 12, 2024
|
Jun 11 |
Presenting on the Emerging Growth Conference 72 Day 1 on June 12 Register Now
|
Jun 3 |
Cadrenal Therapeutics Highlights Presentation of New Trial Data at ISHLT Conference Demonstrating the Importance of Anticoagulation Quality in LVAD Patients
|
May 23 |
Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024
|
May 9 |
Cadrenal Therapeutics Provides First Quarter 2024 Corporate Update
|
Apr 20 |
Favourable Signals For Cadrenal Therapeutics: Numerous Insiders Acquired Stock
|
Apr 11 |
Cadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024
|
Apr 9 |
Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts
|
Mar 12 |
Cadrenal Therapeutics files for $100M mixed shelf
|